Results of trimodality therapy in patients with stage IIIA (N2-bulky) and stage IIIB non-small-cell lung cancer

Clinical Lung Cancer

Volumn 10, Issue 5, 2009, Pages 353-359

  Li, Jian ^a   Dai, Chun Hua ^a   Yu, Li Chao ^a   Chen, Ping ^a   Li, Xiao Qin ^a   Shi, Shun Bing ^a   Wu, Jing Rong ^a  

^a AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

Author keywords

Cisplatin; Induction chemoradiation therapy; Pathologic response; Vindesine

Indexed keywords

CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; MITOMYCIN; VINDESINE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PROGNOSIS; SEPSIS; THORACOTOMY; THROMBOCYTOPENIA; VOMITING;

EID: 77249103099     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2009.n.048     Document Type: Article

References (31)

1. Bulzebruck H, Bopp R, Drings P, et al. New aspects in the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification. Cancer 1992; 70:1102-1110
2. Ruckdeschel JC. Combined modality therapy of non-small cell lung cancer. Semin Oncol 1997; 24:427-439
3. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycim, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17:2692-2699
4. Eberhardt WE, Albain KS, Pass H, et al. Induction treatment before surgery for non-small cell lung cancer. Lung Cancer 2003; 42(suppl 1):S9-14.
5. Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotheray and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: a meta-analysis. Cancer 1995; 76:593-601.
6. Sause W, Kolesar P, Taylor S IV, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Sowthwest Oncology Group. Chest 2000; 117:358-364
7. Socinski MA, Zhang C, Herndon JE II, et al. Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. Ann Oncol 2004; 15:1033-1041
8. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stage IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995; 13:1880-1892.
9. Sugarbaker DJ, Herndon J, Kohman LJ, et al. Results of cancer and leukemia group B protocal 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. J Thorac Cardiovasc Surg 1995; 109:473-483.
10. Choi NC, Carey RW, Daly W, et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol 1997; 15:712-722 (Pubitemid 27074241)
11. Grunenwald DH, Addré F, Le Péchoux C, et al. Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer. J Thorac Cardiovasc Surg 2001; 122:796-800.
12. Thomas M, Rübe C, Semik M, et al. Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer. J Clin Oncol 1999; 17:1185-1193
13. Cyjon A, Nili M, Fink G, et al. Advanced non-small cell lung cancer: induction chemotherapy and chemoradiation before operation. Ann Thorac Surg 2002; 74:342-347
14. Grunenwald DH, Le Chevalier T, Arriagada R, et al. Results of surgical resection in stage IIIB non-small cell lung cancer (NSCLC) after concomitant induction chemo-radiotherapy. Lung Cancer 1997; 18:73.
15. Cappuzzo F, Selvaggi G, Gregorc V, et al. Gemcitabine and cisplatin as induction chemotherapy for patients with unresetable stage IIIA-bulky N2 and stage IIIB nonsmall cell lung carcinoma. Cancer 2003; 98:128-134
16. de Boer RH, Smith IE, Pastorino U, et al. Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer: a randomized feasibility study justifying a multicenter phase III trial. Br J Cancer 1999; 78:1514-1518
17. Mountain CF. A new international staging system for lung cancer. Chest 1986; 89(suppl 4):255-283
18. De Marinis F, Gebbia V. De petris L. Neoadjuvant chemotherapy for stage IIIAN2 non-small cell lung cancer. Ann Oncol 2005; 16(suppl 4):116-122
19. Stinchcombe TE, Fried D, Morris DE, et al. Combined modality therapy for stage III non-small cell lung caner. Oncologist 2006; 11:809-823
20. Grunenwald DH, Albain KS. The potential role of surgery after induction treatment. Semin Radiat Oncol 2004; 14:335-339
21. Skov K, McPhail S. Interaction of platinum drugs with clinically relevant x-ray doses in mammalian cells: a comparison of cisplatin, carboplatin, iproplatin, and telraplatin. Int J Radiat Oncol Biol Phys 1991; 20:221-225
22. Balla I, Michel C, Fritz-Niggle H. Synergistic interaction between vindesine and X-ray in the prenatal development of mice. Int J Radiat Biol 1987; 52:373-383
23. Burkes RL, Ginsberg RJ, Shepherd FA, et al. Induction chemotherapy with mitomycin, vindesine and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto phase II trial. J Clin Oncol 1992; 10:580-586
24. Burkes RL, Shepherd FA, Blackstein ME, et al. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable nonsmallcell lung cancer: final results of the Toronto phase II trial. Lung Cancer 2005; 47:103-109
25. Uy KL, Darling G, Xu W, et al. Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer. J Thorac Cardiovasc Surg 2007; 134:188-193
26. Hoekstra CJ, Stroobants SG, Smit EF, et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:8362-8370
27. Dooms C, Verbeke E, Stroobants S, et al. Prognostic stratification of stage IIIAN2 non-small-cell Lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron eEmission tomography. J Clin Oncol 2005; 26:1128-1134
28. Tanvetyanon T, Eikman EA, Sommers E, et al. Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer. J Clin Oncol 2008; 26:4610-4616
29. Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008; 26:5755-5760
30. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008; 26:2450-2456
31. Okada M, Tsubota N, Yoshimura M, et al. Induction therapy for non-small cell lung cancer with involved mediastinal nodes in multiple stations. Chest 2000; 118:123-128